• Breaking News

    Monday, June 7, 2021

    Home Unlabelled Stock Market - GME up 6475% from 1 year ago

    Stock Market - GME up 6475% from 1 year ago

    June 07, 2021

    Stock Market - GME up 6475% from 1 year ago

    GME up 6475% from 1 year ago

    Posted: 07 Jun 2021 09:28 AM PDT

    Most Anticipated Earnings For This Week! Keep an eye out for $GME ��

    Posted: 07 Jun 2021 04:56 AM PDT

    When people see literally one reddit post on amc and are mad they are only up 15% instead of 500k

    Posted: 07 Jun 2021 04:28 PM PDT

    We are in good hands because the SEC is "monitoring" for market manipulation and ilegal naked short selling just like in 2008

    Posted: 07 Jun 2021 04:49 PM PDT

    Where my apes at??

    Posted: 07 Jun 2021 07:02 PM PDT

    ‘Resist the temptation’ to short AMC Entertainment, other meme stocks ‘because these prices can go to unimaginable highs,’ says Interactive Brokers founder

    Posted: 07 Jun 2021 10:25 AM PDT

    'Resist the temptation' to short AMC Entertainment, other meme stocks 'because these prices can go to unimaginable highs,' says Interactive Brokers founder - MarketWatch

    Published: June 7, 2021 at 11:40 a.m. ET By Mark DeCambre

    Referenced Symbols

    AMC22.92% GME12.87% DJIA-0.42% SPX-0.29% COMP0.10%

    'It is extremely tempting to short these stocks, but unless you have huge liquid resources, please try to resist the temptation because these prices can go to unimaginable highs before they settle down to a reasonable valuation, and you may have to cover on the high point.'

    Trying to bet against stocks like AMC Entertainment Holdings AMC, 23.34% and GameStop Corp. GME, 12.78%, may be a fool's errand and particularly dangerous in a climate of a meme-stock revolution that has helped to propel the value of socially driven assets into the stratosphere.

    Thomas Peterffy, the founder of Interactive Brokers on Monday, during an interview on CNBC's "Squawk Box"said that while it might be extremely tempting to short shares of AMC and others, he would recommend avoiding those stocks altogether.

    Shares of AMC were up more than 19% early Monday and have gained 120% so far in June. GameStop shares are up 9.8% on the session and have enjoyed a 22% climb in the month to date.

    The investments in AMC and GameStop originally started out as organized short-squeezes by a clutch of individual investors who had identified that a number of companies were heavily shorted by hedge funds and surmised, correctly, that those stocks could be pressured higher if enough buyers collectively swooped in.

    The momentum for those assets has continued at an unprecedented level. In the year to date, AMC shares are up 2,555% and those for GameStop have climbed over 1,300% over the period.

    By comparison, the Dow Jones Industrial Average DJIA, -0.42% is up over 13% far this year, the S&P 500 SPX, -0.29% has climbed more than 12%, and the Nasdaq Composite Index COMP, 0.08% has gained more than 7%.

    On Friday, Peterffy warned investors, in an interview with MarketWatch, that investors could lose considerable money betting on meme assets.

    Traditional investing, even trading tenets, have been tossed out the window amid the hype over meme stocks, leaving many veterans and strategists to caution that a liquid market, supported by the Federal Reserve's easy-money policies, may be helping to inflate bubbles in parts of the market and promote FOMO, or fear of missing out.

    That atmosphere is representative of a quote often attributed to financier J.P. Morgan. "Nothing so undermines your financial judgment as the sight of your neighbor getting rich."

    submitted by /u/SavannahSmiles_
    [link] [comments]

    Media catching up. Replaces Hare �� with Ape �� #TortoiseVsApe ����

    Posted: 07 Jun 2021 10:01 AM PDT

    Work from home: Salesforce CEO Benioff disagrees with Jamie Dimon; Sara Eisen interviewer. June 7th

    Posted: 07 Jun 2021 06:17 PM PDT

    Biogen jumps 40%, the numbers behind it. BIIB IBB LABU XBI, 1:56 ��

    Posted: 07 Jun 2021 02:45 PM PDT

    Watchlist For 6/8/2021 -- I am on vacation and still do this because I gotta help my boys eat

    Posted: 07 Jun 2021 06:52 PM PDT

    ����������������������������

    Posted: 07 Jun 2021 07:33 PM PDT

    No Country for HODL Men

    Posted: 07 Jun 2021 07:11 PM PDT

    Yellen_irl

    Posted: 07 Jun 2021 02:42 PM PDT

    Options Traders Bet on Return of $100 Oil

    Posted: 07 Jun 2021 05:21 PM PDT

    Debit (Vertical) spreads are great way to reduce risk and maximize profit. Especially if trading volatile stocks

    Posted: 07 Jun 2021 04:27 PM PDT

    Beware deceptive reporting... Could just as well read "Next 17 years may be sluggish at only 8% annual growth"

    Posted: 07 Jun 2021 01:36 PM PDT

    $1800 Scam? Serious inquiry about this "Cheat Code Algo".

    Posted: 07 Jun 2021 07:05 PM PDT

    I've been watching finance Youtuber "Andrew MoMoney", a very charming young man. About every 20 minutes or so he advocates people go download a service called "Cheat Code Algo"

    I clicked on the link and was presented with a nicely designed website with some pretty wild claims.

    " most accurate "Buy" & "Sell" signals available on the market today period. "

    " Get accurate entry and exit signals that you can rely on to make decisions on when and where you should open and close your positions with the highest odds of success. "

    They also have a graphic with the message "As Seen on: MarketWatch, Business Insider and Yahoo Finance"

    All of this sounds pretty impressive, but for $100-$150 a month this seems pretty fair...? So I was curious to see what the articles said about the service. A startup by two guys who are making people hundreds of thousands of dollars. cool.

    Turns out these three articles were identical and all provided by Pseudo ad agency "Accesswire" (In fact the same article was also posed on several other "news sites", including yahoo sports..)

    I suppose this is a normal practice for businesses to promote themselves.. but it makes me feel sad for what journalism has become.. especially because these "reputable sources" are spreading the word that they can turn anyone's $2000 into $100,000 in a few months.

    I ended up joining their discord to see what their community was like (I was skeptical about the promises but if they really helped people make money, then awesome). There were a quite a few rooms in the discord, including a gallery of very alluring testimonials and highest profits. I asked about the service and how something like this could exist without actually being reported on by mainstream media, and I was greeted with mods telling me I was a troll and to leave if I was too skeptical.

    The people in this group gave me bad vibes man.

    Someone mentioned that it wasn't a scam in response to me asking about the validity of the sales terms used. One lady asked that I hope in a zoom demo they were having for the algorithm to see it in action and ask any questions. I hoped in the zoom call and was called out in front of 30 or so people to ask my questions if I was so skeptical. I denied her request to turn on my microphone and asked just to type my concerns. In response she asked if anyone else had questions, if I wasn't going to speak. I typed my "question" about the claims made on the website, and 2 people told me to get over it and "try and learn about the program". A few more mods / admins were quite rude in the discord and ended up banning me after the zoom had ended. Needless to say I was disappointed with the customer service. 4/10.

    I'm not here to Karen about my experience, but to warn and learn from others about companies like this. Is this a common business model? Could you call it a scam?

    ​

    Thanks for reading and let me know your thoughts.

    submitted by /u/CanYouEvenPhoto
    [link] [comments]

    Options Traders Target Workhorse Stock Amid "Meme Stock" Frenzy

    Posted: 07 Jun 2021 12:01 PM PDT

    Shoutout to my man Jerome

    Posted: 07 Jun 2021 09:11 AM PDT

    Good Start To The Week

    Posted: 07 Jun 2021 06:54 PM PDT

    Just wanted to share the trades that I closed today.

    FUBO 20 Aug 21 45C, 4 contracts: Purchased 6/1/2021

    DBX 16 July 21 28C, 7 contracts: Purchased 6/2/2021

    NIO 16 July 21 40C, 2 contracts: Purchased 6/2/2021

    NIO 20 Aug 21 42C, 1 contract: Purchased 6/3/2021

    NIO 20 Aug 21 50C, 8 contracts: Purchased 6/4/2021

    CLOV 19 Nov 21 10C, 2 contracts: Purchased 6/3/2021

    I'm currently holding:

    PYPL 20 Aug 21 260C, 1 contract: Purchased 6/1/2021

    TWTR 16 July 21 60C, 2 contracts: Purchased 6/2/2021

    PLUG 16 July 21 35C, 2 contracts: Purchased 6/3/2021

    OPEN 16 July 21 23C, 8 contracts: Purchased 6/4/2021

    submitted by /u/OwnFreedom76
    [link] [comments]

    FDA approves much-debated Alzheimer’s drug panned by experts

    Posted: 07 Jun 2021 08:30 AM PDT

    https://finance.yahoo.com/news/fda-approves-much-debated-alzheimer-151611501.html

    MATTHEW PERRONE
    Mon, June 7, 2021, 11:16 AM

    WASHINGTON (AP) — Government health officials on Monday approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease.

    The Food and Drug Administration said it granted approval to the drug developed by Biogen for patients with Alzheimer's disease.

    It's the only drug that U.S. regulators have said can likely treat the underlying disease, rather than manage symptoms like anxiety and insomnia.

    The decision, which could impact millions of older Americans and their families, is certain to spark disagreements among physicians, medical researchers and patient groups. It also has far-reaching implications for the standards used to evaluate experimental therapies, including those that show only incremental benefits.

    The new drug, which Biogen developed with Japan's Eisai Co., did not reverse mental decline, only slowing it in one study. The drug is given as an infusion every four weeks.

    The FDA is requiring the drugmaker to conduct a follow-up study to confirm the drug's benefits for patients. If the study fails to show effectiveness, the FDA could pull the drug from the market, though the agency rarely does so.

    Biogen did not immediately disclose the price, though analysts have estimated the drug could cost between $30,000 and $50,000 for a year's worth of treatment.

    A preliminary analysis by one group found that the drug would need to be priced $2,500 to $8,300 per year to be a good value based on the "small overall health gains" suggested by company studies. The non-profit Institute for Clinical and Economic Review added that "any price is too high" if the drug's benefit isn't confirmed in follow-up studies.

    Nearly 6 million people in the U.S. and many more worldwide have Alzheimer's, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks. In the final stages of the disease, those afflicted lose the ability to swallow. The global burden of the disease, the most common cause of dementia, is only expected to grow as millions more Baby Boomers progress further into their 60s and 70s.

    Aducanumab (pronounced "add-yoo-CAN-yoo-mab") aims to help clear harmful clumps of a protein called beta-amyloid from the brain. Other experimental drugs have done that before but they made no difference in patients' ability to think, care for themselves or live independently.

    The pharmaceutical industry's drug pipeline has been littered for years with failed Alzheimer's treatments, representing billions in research costs. The FDA's greenlight is likely to revive investments in similar therapies previously shelved by drugmakers.

    The new medicine is made from living cells that will have to be given via infusion at a doctor's office or hospital. The most common side effects were inflammation in the brain, most cases did not cause symptoms or lasting problems.

    The FDA's review of the drug has become a flashpoint in longstanding debates over standards used to evaluate therapies for hard-to-treat conditions. On one side, groups representing Alzheimer's patients and their families say any new therapy — even one of small benefit — warrants approval. But many experts have warned that greenlighting the drug could set a dangerous precedent, opening the door to treatments of questionable benefit.

    The approval came despite a scathing assessment in November by the FDA's outside panel of neurological experts. The group voted "no" to a series of questions on whether reanalyzed data from a single study submitted by Biogen showed that the drug was effective.

    Cambridge, Massachusetts-Biogen halted two studies of the drug in 2019 after disappointing results suggested aducanumab would not meet its goal of slowing mental and functional decline in Alzheimer's patients. Several months later, the company reversed course, announcing that a new analysis of one of the studies showed the drug was effective at higher doses and that the FDA had advised that it warranted review. Company scientists said the drug's initial failure was due to some patients not receiving high enough doses to slow the disease.

    But the changes to dosing and the company's after-the-fact analysis made the results hard to interpret, raising the skepticism of many experts, including those on the FDA panel.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

    submitted by /u/SavannahSmiles_
    [link] [comments]

    Next year's HP12C financial calculator to come standard with 3 new buttons to aid in forecasting calculations.

    Posted: 07 Jun 2021 01:43 AM PDT

    Technical Analysis for a couple of Stocks that maybe off the Radar.

    Posted: 07 Jun 2021 04:10 PM PDT

    Hello: I just wanted to let everyone know about a couple of stocks that might be off of investors radar. The two stocks that I am interested in are TGB and ISR. Both stocks are set up for more gains going forward for a couple of different reasons. TGB is a small metals mining company that has a huge interest in Copper. The Florence Copper project is set to gain approval for business this month as soon as the EPA permit is granted. With the supply and demand situation surrounding Copper means that this company has a long way to run in the future. As far as ISR goes, the company is set to resume where they left off before the pandemic stopped everything in its tracks including elective hospital procedures which this company participates in with their treatment for early stage cancers especially prostate cancer. These treatments should resume this quarter and continue into the end of the year. They are flush with cash and have no debt. Should be a huge winner going forward with these procedures pickup and others are added with further approval and adoption.

    submitted by /u/Original-Increase243
    [link] [comments]

    Wall Street body proposes new rules on short positions, stock loans

    Posted: 07 Jun 2021 07:41 PM PDT

    Spectrum Pharmaceuticals sppi get in now

    Posted: 07 Jun 2021 10:24 AM PDT

    Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.

    This is very undervalues stock. Currently sitting at around 4.12. It gone up over 50 c in the last two weeks. There target is 8 to 12 dollors with everything analysis I have seen points to this going to 8 plus. And it's not a Reddit stock.

    submitted by /u/Glad_Ad510
    [link] [comments]
    Read more
    at

    No comments:

    Post a Comment